Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2024 | Overweight → Sector Weight | KeyBanc Capital Markets | |
| 1/3/2024 | $14.00 | Overweight | Barclays |
| 1/3/2024 | $11.00 | In-line → Outperform | Evercore ISI |
| 12/13/2023 | $14.00 → $11.00 | Neutral → Overweight | JP Morgan |
| 11/13/2023 | $12.00 → $11.00 | Neutral → Overweight | Piper Sandler |
| 8/1/2023 | $16.00 | Overweight | Cantor Fitzgerald |
| 5/10/2023 | Outperform → Mkt Perform | Raymond James | |
| 5/10/2023 | Buy → Neutral | Guggenheim |
In the last three months, 4 analysts have published ratings on Health Catalyst (NASDAQ:HCAT), offering a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for Health Catalyst, revealing an average target of $11.5, a high estimate of $14.00, and a low estimate of $8.00. A negative shift in sentiment is evident as a
Evercore ISI Group analyst Elizabeth Anderson maintains Health Catalyst (NASDAQ:HCAT) with a Outperform and lowers the price target from $9 to $8.
Throughout the last three months, 4 analysts have evaluated Health Catalyst (NASDAQ:HCAT), offering a diverse set of opinions from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0 Last 30D 0 1 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for Health Catalyst, presenting an average target of $13.5, a high estimate of $16.00, and a low estimate of $11.00. Marking an increase of 1.28%, the
SALT LAKE CITY, Nov. 20, 2024 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the launch of an AI-powered version of BluePrint Protect™ from Intraprise Health, LLC ("Intraprise Health"), a platform that empowers healthcare organizations to screen and identify risks related to cybersecurity threats through third parties. On Nov. 6, Health Catalyst announced it signed a definitive agreement to acquire Intraprise Health, a tech-enabled cybersecuri
SALT LAKE CITY, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that members of leadership will participate in the following upcoming investor conferences: The Citi 2024 Global Healthcare Conference, being held in Miami, including a fireside chat with Dan Burton, Chief Executive Officer, and Jason Alger, Chief Financial Officer, on Tuesday, December 3, 2024, at 2:30 pm ET.The 7th Annual Evercore HealthCONx Conference, being held in Miami, including a fireside chat with Dan Burton, Chief Executive Officer, and Jason Alger, Chief Financ
SALT LAKE CITY, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, Dan LeSueur, Chief Operating Officer, and Jack Knight, Vice President of Investor Relations, will participate in the Stephens Annual Investment Conference, being held in Nashville, including a fireside chat on Wednesday, November 20, 2024, at 1:00 pm CT. About Health Catalyst Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations and is
KeyBanc Capital Markets downgraded Health Catalyst from Overweight to Sector Weight
Barclays initiated coverage of Health Catalyst with a rating of Overweight and set a new price target of $14.00
Evercore ISI upgraded Health Catalyst from In-line to Outperform and set a new price target of $11.00
4 - Health Catalyst, Inc. (0001636422) (Issuer)
SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)
SC 13G - Health Catalyst, Inc. (0001636422) (Subject)
SC 13G/A - Health Catalyst, Inc. (0001636422) (Subject)
SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Jill Hoggard Green, RN, BSN, MS, PhD, FAAN, former Chief Executive Officer of The Queen's Health Systems, has been appointed to serve as a member of Health Catalyst's board of directors ("Board") and a member of its Compensation Committee, effective December 1, 2024. "Jill has been an extraordinary leader throughout her career. With an impressive tenure in hea
SALT LAKE CITY, June 6, 2024 /PRNewswire/ -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has successfully completed its acquisition of Carevive Systems ("Carevive"), a leading oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Oncology providers and life science researchers use Carevive's flagship platform and/or Carevive data in routine clinical practice for treatment care plan
Dr. Jennifer Doudna, Dr. Michael Pfeffer, Gregory Robinson & More Join HAS 2024 SALT LAKE CITY, Feb. 2, 2024 /PRNewswire/ -- The Healthcare Analytics Summit (HAS), an annual interactive and educational event for the healthcare industry, today announced its keynote and session speaker lineup for the 2024 event. In its tenth year, HAS 24 is the premier event showcasing data and analytics' critical role in tackling some of healthcare's greatest challenges. HAS 24 convenes national experts whose leadership in data and analytics, machine learning, AI, and healthcare technology have
8-K - Health Catalyst, Inc. (0001636422) (Filer)
D - Health Catalyst, Inc. (0001636422) (Filer)
10-Q - Health Catalyst, Inc. (0001636422) (Filer)
SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (("Health Catalyst, NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended September 30, 2024. "For the third quarter of 2024, I am pleased with our strong financial results, including total revenue of $76.4 million and Adjusted EBITDA of $7.3 million, with these results exceeding the mid-point of our quarterly guidance on each metric. This financial performance continues to demonstrate our ability to scale as we remain focused on driving profitable growth. We are encouraged with our bookings results through Q3
SALT LAKE CITY, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst", , NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its third quarter 2024 operating results on Wednesday, November 6, 2024, after market close. In conjunction, the company will host a conference call to review the results at 4:30 pm ET on the same day. Conference Call Details The conference call can be accessed by dialing 800-343-5172 for U.S. participants, or 203-518-9856 for international participants, and referencing conference ID "HCATQ324." A live audio webcast will be available online at https://ir.healthcatal
SALT LAKE CITY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ((", Health Catalyst, ", NASDAQ:HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter ended June 30, 2024. "For the second quarter of 2024, I am pleased by our strong financial results, including total revenue of $75.9 million and Adjusted EBITDA of $7.5 million, with these results exceeding the mid-point of our quarterly guidance on each metric. I am also pleased with our bookings performance through Q2 2024, especially as it relates to our net new Platform Subscription Clients. In the first half of 2024 we signed more net
4 - Health Catalyst, Inc. (0001636422) (Issuer)
4 - Health Catalyst, Inc. (0001636422) (Issuer)
4 - Health Catalyst, Inc. (0001636422) (Issuer)